Strides Pharma Science Ltd Sees Mixed Technical Signals Amid Price Momentum Shift

Price Momentum and Recent Market Performance

Currently trading at ₹955.85, down 1.21% from the previous close of ₹967.55, Strides Pharma Science Ltd remains below its 52-week high of ₹1,024.90 but comfortably above the 52-week low of ₹530.70. The intraday range on 12 Jan 2026 spanned ₹937.40 to ₹976.60, reflecting moderate volatility. This price action comes amid a broader shift in technical momentum, with the overall trend moving from bullish to mildly bullish.

Examining returns relative to the benchmark Sensex reveals Strides Pharma’s strong outperformance over multiple time horizons. Over the past week, the stock gained 5.86% compared to the Sensex’s decline of 2.55%. The one-month return stands at 7.35% versus the Sensex’s -1.29%, while year-to-date gains are 5.93% against a -1.93% benchmark. Over the longer term, Strides has delivered a remarkable 41.61% return over one year and an extraordinary 463.53% over three years, dwarfing the Sensex’s respective 7.67% and 37.58% gains. Even on a five-year basis, the stock’s 110.96% return outpaces the Sensex’s 71.32%, though the 10-year return of 62.14% trails the Sensex’s 235.19%.

Technical Indicator Analysis: Mixed Signals Across Timeframes

The technical landscape for Strides Pharma is characterised by a divergence of signals across weekly and monthly timeframes, underscoring the complexity of its current momentum shift.

MACD (Moving Average Convergence Divergence): On a weekly basis, the MACD indicator has turned mildly bearish, suggesting a potential weakening in short-term momentum. However, the monthly MACD remains bullish, indicating that the longer-term trend retains upward bias. This divergence suggests that while short-term caution is warranted, the broader trend remains constructive.

RSI (Relative Strength Index): Both weekly and monthly RSI readings currently show no definitive signal, hovering in neutral territory. This lack of overbought or oversold conditions implies that the stock is not exhibiting extreme momentum in either direction, leaving room for potential directional moves based on other factors.

Bollinger Bands: Both weekly and monthly Bollinger Bands are bullish, signalling that price volatility is contained within an upward trending range. This supports the notion that despite short-term fluctuations, the stock’s price action remains structurally positive.

Moving Averages: Daily moving averages are bullish, reinforcing the short-term upward momentum. This is a positive sign for traders looking for confirmation of sustained buying interest.

KST (Know Sure Thing): The weekly KST indicator is bullish, aligning with the daily moving averages, but the monthly KST is mildly bearish. This again highlights the contrast between short-term strength and longer-term caution.

Dow Theory: Weekly readings are mildly bullish, while monthly readings are mildly bearish, reflecting the mixed technical environment and the need for investors to monitor developments closely.

On-Balance Volume (OBV): Weekly OBV is mildly bullish, indicating that volume trends support recent price gains. Conversely, monthly OBV is mildly bearish, suggesting that longer-term volume patterns may not fully confirm the price strength.

Mojo Score and Rating Upgrade

Reflecting these technical developments, Strides Pharma Science Ltd’s Mojo Score currently stands at 50.0, with a Mojo Grade of Hold. This represents an upgrade from a previous Sell rating as of 29 Sep 2025, signalling improved confidence in the stock’s near-term prospects. The Market Cap Grade is 3, indicating a mid-tier market capitalisation relative to peers in the Pharmaceuticals & Biotechnology sector.

The upgrade to Hold suggests that while the stock is no longer viewed as a sell candidate, it has yet to demonstrate the strength required for a Buy rating. Investors should weigh this balanced outlook against the mixed technical signals and recent price momentum.

Sector and Industry Context

Strides Pharma operates within the Pharmaceuticals & Biotechnology sector, a space characterised by innovation-driven growth and regulatory sensitivities. The sector’s performance often hinges on product pipelines, approvals, and broader healthcare trends. Strides’ technical indicators, combined with its strong relative returns over multiple periods, position it as a noteworthy player within this competitive landscape.

However, the mildly bearish monthly technicals and neutral RSI readings suggest that investors should remain vigilant for potential volatility or sector-specific headwinds that could impact the stock’s trajectory.

Investor Takeaways and Outlook

For investors analysing Strides Pharma Science Ltd, the current technical parameter changes highlight a nuanced momentum shift. The stock’s short-term indicators, including daily moving averages and weekly KST, remain bullish, supporting the case for continued upward price movement in the near term. Conversely, monthly indicators such as MACD, KST, Dow Theory, and OBV present a more cautious picture, signalling potential resistance or consolidation ahead.

Given the stock’s strong outperformance relative to the Sensex over one week, one month, year-to-date, and longer horizons, Strides remains an attractive candidate for investors seeking exposure to the Pharmaceuticals & Biotechnology sector. Yet, the mixed technical signals counsel a measured approach, with attention to evolving price action and volume trends.

In summary, Strides Pharma Science Ltd’s technical landscape is characterised by a transition from bullish to mildly bullish momentum, with a blend of positive and cautionary signals across timeframes. The recent Mojo Grade upgrade to Hold reflects this balanced outlook, suggesting that investors should monitor developments closely while recognising the stock’s strong relative performance and sector positioning.

Conclusion

Strides Pharma Science Ltd’s recent technical parameter changes underscore a complex momentum environment. While short-term indicators remain supportive, longer-term signals urge caution. The stock’s strong relative returns and upgraded Mojo Grade to Hold reflect improved sentiment, yet investors should remain alert to evolving market dynamics and sector developments. Careful monitoring of MACD, RSI, moving averages, and volume trends will be essential to gauge the sustainability of the current momentum and to identify optimal entry or exit points.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →